Why Johnson & Johnson's CEO Welcomes ScrutinyJohnson & Johnson is reshaping its portfolio by investing heavily in R&D and addressing legal challenges post-split from its consumer health division.
Johnson & Johnson ketamine-derived nasal spray gets FDA approval for depression, but JNJ stock dips on earningsThe FDA approved Spravato, a nasal spray for treatment-resistant depression, offering quicker symptom relief than traditional oral antidepressants.
FDA proposes new tests to detect asbestos in cosmetics and other products containing talcThe FDA proposes testing talc-based products for asbestos to ensure consumer safety, but does not ban talc outright.
Prediction: Johnson & Johnson's Dividend Payouts Will Increase in 2025Dividend stocks provide investors with consistent income and long-term total returns from dividends and capital gains.
Johnson & Johnson Just Paid Investors: Here's How Much They ReceivedJohnson & Johnson rewards shareholders with a consistent dividend, reinforcing its commitment despite recent stock underperformance.
Prediction: Johnson & Johnson's Dividend Payouts Will Increase in 2025Dividend stocks provide investors with consistent income and long-term total returns from dividends and capital gains.
Johnson & Johnson Just Paid Investors: Here's How Much They ReceivedJohnson & Johnson rewards shareholders with a consistent dividend, reinforcing its commitment despite recent stock underperformance.
NY AG James secures $700M judgment against Johnson & Johnson in talcum powder probeJohnson & Johnson fined $700 million for deceptive marketing of talcum powder products.
Women plan UK legal action over talc cancer claimsWomen in the UK are suing Johnson & Johnson for alleged links between talc and cancer, with numerous claimants involved.
NY AG James secures $700M judgment against Johnson & Johnson in talcum powder probeJohnson & Johnson fined $700 million for deceptive marketing of talcum powder products.
Women plan UK legal action over talc cancer claimsWomen in the UK are suing Johnson & Johnson for alleged links between talc and cancer, with numerous claimants involved.
J&J Backs Down From 340B Rebates, But Maintains They're 'Legally Permissible' Per Statute - MedCity NewsJohson & Johnson's attempted changes to the 340B program sparked controversy and scrutiny, emphasizing the program's role in providing drug discounts for underserved communities.
Roy Butler inquest: Covid vaccine firm says 'insufficient evidence' for link to fatal brain bleedsThe Janssen vaccine was linked to multiple cases of brain bleeds, but Johnson & Johnson found insufficient evidence to establish a causal relationship.
Roy Butler inquest: Covid vaccine firm warns 'insufficient evidence' for link to fatal brain bleedsJohnson & Johnson claims insufficient evidence links brain bleeds to their vaccine, despite some incidents reported after vaccination.
Roy Butler inquest: Covid vaccine firm says 'insufficient evidence' for link to fatal brain bleedsThe Janssen vaccine was linked to multiple cases of brain bleeds, but Johnson & Johnson found insufficient evidence to establish a causal relationship.
Roy Butler inquest: Covid vaccine firm warns 'insufficient evidence' for link to fatal brain bleedsJohnson & Johnson claims insufficient evidence links brain bleeds to their vaccine, despite some incidents reported after vaccination.
Johnson & Johnson's $390 billion dilemmaJohnson & Johnson leads in healthcare stocks with $390 billion market cap, but growth has been modest.The company is focused on expanding through acquisitions and internal development of new products.